157 results on '"Klimm, Beate"'
Search Results
2. Hodgkin-Lymphom
3. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group
4. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
5. Hodgkin lymphoma
6. Population Pharmacokinetics of the BEACOPP Polychemotherapy Regimen in Hodgkin’s Lymphoma and its Effect on Myelotoxicity
7. First-line treatment of Hodgkin’s lymphoma
8. Current treatment strategies of the German Hodgkin Study Group (GHSG)
9. Hodgkin lymphoma: a curable disease: what comes next?
10. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies
11. Role of Hematotoxicity and Sex in Patients With Hodgkinʼs Lymphoma: An Analysis From the German Hodgkin Study Group
12. Secondary Amenorrhea After Hodgkinʼs Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkinʼs Lymphoma Study Group
13. Current treatment strategies of the German Hodgkin Study Group (GHSG)
14. Hodgkin lymphoma: a curable disease: what comes next?
15. Axillary swelling and a reduced general condition in a middle-aged man
16. Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
17. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
18. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant
19. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
20. Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors
21. Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients
22. The Effect of Specialized Cancer Treatment Centers on Treatment Efficacy in Hodgkin's Lymphoma
23. Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)
24. Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
25. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant
26. Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
27. Treatment-Related Mortality in Patients With Advanced-Stage Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group
28. The Effect of Specialized Cancer Treatment Centers on Treatment Efficacy in Hodgkin’s Lymphoma
29. Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone
30. Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients
31. Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).
32. Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors
33. Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
34. Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)
35. Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
36. Combined Modality Treatment of Hodgkin’s Lymphoma
37. Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG).
38. Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).
39. Maladie de Hodgkin
40. The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy.
41. Secondary Amenorrhoea after Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin Lymphoma Study Group (GHSG).
42. Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.
43. Activation of p90RSK and growth stimulation of multicellular tumor spheroids are dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP
44. Hodgkin's Lymphoma in the Elderly: A Different Disease in Patients Over 60.
45. Adressenverzeichnis
46. CHAPTER 77 - HODGKIN LYMPHOMA: CLINICAL MANIFESTATIONS, STAGING, AND THERAPY
47. CHAPTER 40 - HODGKIN'S LYMPHOMA
48. CONTRIBUTORS
49. CONTRIBUTORS
50. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.